Abstract: Hepatitis A virus is attenuated in virulence by in vitro passage in susceptible cell cultures, without prior passage in a subhuman primate. This process results in a live, attenuated hepatitis A virus vaccine suitable for human disease prevention.
Type:
Grant
Filed:
February 10, 1993
Date of Patent:
May 7, 1996
Assignee:
Merck & Co., Inc.
Inventors:
Paula A. Giesa, Philip J. Provost, Maurice R. Hilleman